HBV 接种疫苗

zasxz

HBV VACCINATION

Long-term follow-up of a randomized trial. Man-Fung Yuen and colleagues from the University of Hong Kong tested long-term immunogenicity in 88 subjects who had participated in a HBV vaccination study 18 years earlier. The subjects had been randomized to receive 3 different HBV vaccination regimens: 2-dose recombinant; 3-dose recombinant; and 3-dose plasma-derived vaccines. The two 3-dose vaccine regimen groups had a significantly higher geometric mean titer of anti-HBs and a higher proportion of subjects with anti-HBs titers ≥10 mIU/mL than the 2-dose regimen group. No differences were found between subjects receiving the 3-dose recombinant and the 3-dose plasma-derived vaccine regimens. Anamnestic responses were documented in 70 subjects and no subject became HBsAg(+). Benign breakthrough HBV infection, indicated by isolated anti-HBc positivity, occurred in 3 patients. These findings showed that the 3-dose regimens were more effective than the 2-dose regimen and that a booster dose was not necessary for up to 18 years after the primary vaccination, but the number of subjects studied was small. (Yuen M-F, et al. Clin Gastroenterol Hepatol 2004;2:941-945)